Clinical trials: Advanced Solid Tumor (Phase 1)
Neoplasms
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
- Trial name
- NCT06311578
- Testing
- JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 126 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumors
A Study of DXC018 in Patients With Advanced Solid Tumors
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC018 in participants…
- Trial name
- NCT07849218
- Testing
- DXC018
- Where
- 4 sites in China
- Volunteers
- 110 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Advanced Solid Tumors
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
In many types of human tumors, PD-L1 is highly expressed. Such high expression has often been associated with poor prognosis in cancer patients.
- Trial name
- NCT03133247
- Testing
- SHR-1316
- Where
- Australia
- Volunteers
- 37 people
- Sponsor
- Atridia Pty Ltd.
Advanced or Metastatic Solid Tumors
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid…
- Trial name
- NCT06548217
- Testing
- ONO-4538HSC
- Where
- 8 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumors
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes…
- Trial name
- NCT05881525
- Testing
- TC-N201 cells, IL-2, Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- TCRCure Biopharma Ltd.
Solid Tumor
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.
- Trial name
- NCT06220318
- Testing
- C019199, Sintilimab
- Where
- 2 sites in China
- Volunteers
- 155 people
- Sponsor
- Fujian Haixi Pharmaceuticals Co., Ltd.
Solid Tumor
A Study of ASP1012 in Adults With Solid Tumors
ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers. ASP1012 was changed in a laboratory to infect and kill cancer cells, leaving healthy cells alone.
- Trial name
- NCT06171178
- Testing
- ASP1012, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Neoplasms, Breast Neoplasms
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
This study is comprised of two portions: a Phase 1 portion and a Phase 2 portion. The Phase 1 portion is a single-country, non-randomized, open label, clinical trial which will evaluate the safety, tolerability, preliminary…
- Trial name
- NCT01684215
- Testing
- PD-0332991, letrozole
- Where
- 16 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Pfizer
Solid Tumor
A Study in Participants With Advanced Solid Tumors
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available.
- Trial name
- NCT01682135
- Testing
- Ramucirumab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Neoplasms
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm.
- Trial name
- NCT03416335
- Testing
- DSP-0509, DSP-0509, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADVANCED SOLID TUMORS
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors
- Trial name
- NCT00877474
- Testing
- PM01183
- Where
- 2 sites in United States, Spain
- Volunteers
- 30 people
- Sponsor
- PharmaMar
Cancer, Lymphoma
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous…
- Trial name
- NCT00526838
- Testing
- XL228
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Exelixis
Advanced Solid Tumors
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.
- Trial name
- NCT00785538
- Testing
- IMC-A12
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
This is a Phase I, open-label, multi-center, dose-finding study to assess the safety, pharmacokinetics, and preliminary efficacy of ET0038 in patients with advanced solid tumors.
- Trial name
- FIRST (NCT05525559)
- Testing
- ET0038
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
Advanced Solid Tumors
Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors
This is an open-label, multicenter, dose-escalation phase I study to assess the safety, tolerability and preliminary efficacy of KN044 in participants with all advanced solid tumors who are not able to have current standard…
- Trial name
- NCT04126590
- Testing
- KN044
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Solid Tumor
Clinical Study of KD6001 in Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability and clinical activity of KD6001 as treatment for participants with advanced solid tumours.
- Trial name
- NCT05230290
- Testing
- KD6001 Injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Cancer, Solid Tumors
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
- Conditions
- Cancer, Solid Tumors, Advanced Solid Malignancies
- Trial name
- NCT00973076
- Testing
- AZD8055
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- AstraZeneca